Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34+ blood progenitor cells

International Journal of Immunopathology and Pharmacology

Volumn 17, Issue 3, 2004, Pages 255-263

  Mu, L J ^a   Lazarova, P ^a   Gaudernack, G ^a   Saeboe Larssen S ^a   Kvalheim, Gunnar ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cancer vaccines; CD34+ cell derived dendritic cells; mRNA transfected

Indexed keywords

ANTIGEN; CD34 ANTIGEN; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; POLITEF; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL MATURATION; CELLGRODC MEDIUM; CELLGROSCGM MEDIUM; CONTROLLED STUDY; CRYOPRESERVATION; CULTURE MEDIUM; DENDRITIC CELL; DRUG MEGADOSE; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKAPHERESIS; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; STEM CELL; T LYMPHOCYTE ACTIVATION; THAWING;

EID: 8344227701     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200401700305     Document Type: Article

References (26)

1. Banchereau J. and R.M. Steinman. 1998. Dedritic cells and control of immunity. Nature 392:245.
2. Banchereau J., F. Briere, C. Caux, J. Davoust, S. Lebecue, Y. Liu, B. Pulendran and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.
3. Thurner B., C. Roder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Keikavoussi, E. Kampfen, A. Bender and G. Schuler. 1999. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223:1.
4. Feuerstein B., T. Berger, C. Maczek, C. Roder, D. Schreiner, U. Hirsch, I. Haendle, W. Leisgang, A. Glaser, O. Kuss, T. Diepgen, G. Schuler and B. Thurner. 2000. A method for the production of cryopreserved aliquots of antigen- preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods 245:15.
5. Maria R. Motta, M. Castellani, S. Rizzi, A. Curti, F. Gubinelli, M. Fogli, E. Ferri, C. Cellini, M. Baccarani and R. Lemoli. 2003 Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br. J. Haematol. 121:240.
6. Ramadan G., R. Schmidt and J. Schubert. 2001 In vitro generation of human CD86+ dendritic cells from CD34+ haematopoietic progenitors by PMA and in serum-free medium. Clinical Exp. Immunol. 126:180.
7. Strunk D., K. Rappersberger, K. Egger, et al. 1996. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 87:1292
8. Enomoto M., H. Nagayama, K. Sato, Y. Xu, S. Asano and T.A. Takahashi. 2000. In vitro generation of dendritic cells derived from cryopreserved CD34+ cells mobilized into peripheral blood in lymphoma patients. Cytotherapy 2:95.
9. Titzer S., O. Christensen, O. Manzke, H. Tesch, J. Wolf, B. Emmerich, C. Carsten, V. Diehl and H. Bohlen. 2000. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 108:805.
10. Ferlazzo G., A. Wesa, W. Wie and A. Galy. 1999. Dendritic Cells generated either from D34+ progenitor cells or from monocytes differ in their ability to activate antigen- specific CD8+ T cells J. Immunol. 163:3597.
11. Banchereau J., A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K.M. Wittkowski, N. Bhardwaj, L. Pineiro, R. Steinman and J. Fay. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34 (+) progenitor-derived dendritic cell vaccine. Cancer Res. 6:645.1
12. Mackensen A., B. Herbst, J. Chen, G. Kohler, C. Noppen, W. Herr, G. Spagnoli, V. Cerundolo and A. Lindemann. 2000. Phase 1 study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitorcells. Int. J. Cancer 86:385.
13. Luft T., K. Pang, E. Thomas, C. Bradley, H. Savoia, J. Trapani and J. Cebon. 1998. A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp. Hematol. 26:489
14. Kowalkowski K., M. Alzona, F. Aono, D. Van Epps and M. Vachula. 1998. Ex Vivo Generation of Dendritic Cells from CD34+ Cells in Gas-Permeable containers Under Serum-Free Conditions. J. Hematotherapy 7:403.
15. Mu L.J., G. Gaudernack, S. Sæbøe-Larssen, H. Hammerstad, A. Tierens and G. Kvalheim. 2003. A Protocol for Generation of Clinical Grade mRNA-Transfected Monocyte-Derived Dendritic Cells for Cancer Vaccines Scandinavian J. Immunol. 58:578.
16. Blystad A.K., H. Holte, S. Kvaløy, E. Smeland, J. Delabie and G. Kvalheim. 2001. High-dose therapy in patients with Hodgkin disease: the use of selected CD34+ cells is as safe as unmanipulated peripheral progenitor cells (PBPC). Bone Marrow Transplant. 28:849.
17. Sæbøe-Larssen S., E. Fossberg and G. Gaudernack. 2002. mRNA-based electrotransfection of human dendritic cells and induction of T-lymphocyte responses against the telomerase catalytic subunit (hTERT). J. Immunol. Methods 1:191.
18. Kvalheim G. 2002. Clinical use of enriched CD34+ cells. Blood Therapies Medicine 2:57.
19. Porgador A. and E. Gilboa. 1995, Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
20. Sallusto F. and A. Lanzavecchia, 1994, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF plus IL-4 and downregulated by TNF-alpha. J. Exp. Med. 179:1109.
21. Caux C., C. Dezutter-Dambuyant, D. Schmitt and J. Banchereau. 1992. GM-CSF and TNF-alpha cooperate in the generation of dendritic langerhans cells. Nature 360:258
22. Curti A., M. Fogli, M. Ratta, S. Tura and R. Lemoli 2001. Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+ DR dendritic cell precursors. J. Immunol. 166:848.
23. s enhance the terminal differentiation of DC. J. Immunol. 161:1947.
24. Gilboa E., S.K. Nair and H. Kim Lyerly 1998. Immunotherapy of cancer with dendritic- cell-based vaccines. Cancer Immunol. Immunother. 46:82.
25. Boczkowski B., S. K. Nair, J. Nam, H. Lyerly and E. Gilboa 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60:1028
26. Arlen P.M., J. L.Gulley, C. Palena, J. Marshall, J. Schlom and K.-Y. Tsang 2003. A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. J. Immunol. Methods 279:183